I-Mab
(NASDAQ : IMAB)

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.52%168.970.7%$1409.97m
PFEPfizer Inc. -0.61%36.040.9%$1187.98m
LLYEli Lilly & Co. -1.96%203.711.1%$1053.73m
ABBVAbbVie, Inc. 0.52%103.201.9%$745.54m
MRKMerck & Co., Inc. -0.01%77.080.7%$708.33m
BMYBristol-Myers Squibb Co. 0.00%62.021.0%$696.22m
AZNAstraZeneca Plc -0.35%51.921.2%$671.14m
ARCTArcturus Therapeutics Holdings, Inc. 0.00%67.200.0%$223.89m
NVSNovartis AG 0.65%93.500.2%$204.64m
VTRSViatris, Inc. -1.54%16.600.0%$194.24m
RPRXRoyalty Pharma Plc 0.00%50.310.2%$174.96m
GSKGlaxoSmithKline Plc -0.18%38.110.2%$161.88m
SNYSanofi 0.55%47.590.2%$135.92m
GRTSGritstone Oncology, Inc. -0.69%17.180.0%$133.93m
TAKTakeda Pharmaceutical Co., Ltd. 0.29%17.600.0%$84.51m

Company Profile

I-Mab operates as a clinical stage biopharmaceutical company. It engages in the development and commercialization of biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China.